SATB2 and carcinosarcoma: Thus, the combined assessment of SATB2 protein expression and TP53 gene mutation status is crucial for differentiating PHO from other hepatic malignancies, including hepatic cystadenocarcinoma, cholangiocarcinoma and carcinosarcoma.